Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
Identifieur interne : 001611 ( Main/Corpus ); précédent : 001610; suivant : 001612Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
Auteurs : Hiroshi Nagayama ; Masayuki Ueda ; Mineo Yamazaki ; Yasuhiro Nishiyama ; Makoto Hamamoto ; Yasuo KatayamaSource :
- Movement Disorders [ 0885-3185 ] ; 2010-08-15.
English descriptors
Abstract
[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23338
Links to Exploration step
ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23338</idno><idno type="url">https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001611</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name><affiliation><mods:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1744">1744</biblScope><biblScope unit="page" to="1747">1747</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><idno type="DOI">10.1002/mds.23338</idno><idno type="ArticleID">MDS23338</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MIBG</term><term>multiple system atrophy</term><term>myocardial scintigraphy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hiroshi Nagayama MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Masayuki Ueda MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Mineo Yamazaki MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Yasuhiro Nishiyama MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Makoto Hamamoto MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Yasuo Katayama MD</name><affiliations><json:string>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>MIBG</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>myocardial scintigraphy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item></subject><articleId><json:string>MDS23338</json:string></articleId><language><json:string>eng</json:string></language><abstract>[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.37</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1061</abstractCharCount><pdfWordCount>4510</pdfWordCount><pdfCharCount>29891</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>155</abstractWordCount></qualityIndicators><title>Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><genre><json:string>brief communication</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>1747</last><first>1744</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23338</json:string></doi><id>0E7C00AA65D43F1FDA7276F00F617A72913D7337</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: All authors have no financial disclosure or conflicts of interest related to this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><persName><forename type="first">Hiroshi</forename><surname>Nagayama</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, 1‐1‐5 Sendagi Bunkyo‐ku, Tokyo 113‐8603, Japan</p></note><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Masayuki</forename><surname>Ueda</surname></persName><roleName type="degree">MD</roleName><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Mineo</forename><surname>Yamazaki</surname></persName><roleName type="degree">MD</roleName><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Yasuhiro</forename><surname>Nishiyama</surname></persName><roleName type="degree">MD</roleName><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Makoto</forename><surname>Hamamoto</surname></persName><roleName type="degree">MD</roleName><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Yasuo</forename><surname>Katayama</surname></persName><roleName type="degree">MD</roleName><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1744">1744</biblScope><biblScope unit="page" to="1747">1747</biblScope></imprint></monogr><idno type="istex">0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><idno type="DOI">10.1002/mds.23338</idno><idno type="ArticleID">MDS23338</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>MIBG</term></item><item><term>myocardial scintigraphy</term></item><item><term>multiple system atrophy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-11-22">Received</change><change when="2010-06-09">Registration</change><change when="2010-08-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v25:11</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2010-08-15">15 August 2010</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="290" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23338</doi><idGroup><id type="unit" value="MDS23338"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-11-22"></event><event type="manuscriptRevised" date="2010-03-06"></event><event type="manuscriptAccepted" date="2010-06-09"></event><event type="firstOnline" date="2010-07-19"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-07-19"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="publishedOnlineFinalForm" date="2010-08-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1744</numbering><numbering type="pageLast">1747</numbering></numberingGroup><correspondenceTo>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, 1‐1‐5 Sendagi Bunkyo‐ku, Tokyo 113‐8603, Japan</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23338.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2338"></count></countGroup><titleGroup><title type="main" xml:lang="en">Abnormal cardiac [<sup>123</sup>I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy<link href="#fn1"></link></title><title type="short" xml:lang="en">Abnormal Cardiac MIBG Uptake in MSA</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Hiroshi</givenNames><familyName>Nagayama</familyName><degrees>MD</degrees></personName><contactDetails><email>nagayama@nms.ac.jp</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Masayuki</givenNames><familyName>Ueda</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mineo</givenNames><familyName>Yamazaki</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yasuhiro</givenNames><familyName>Nishiyama</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Makoto</givenNames><familyName>Hamamoto</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yasuo</givenNames><familyName>Katayama</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="JP" type="organization"><unparsedAffiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">MIBG</keyword><keyword xml:id="kwd2">myocardial scintigraphy</keyword><keyword xml:id="kwd3">multiple system atrophy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>[<sup>123</sup>I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: All authors have no financial disclosure or conflicts of interest related to this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Abnormal Cardiac MIBG Uptake in MSA</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Abnormal cardiac [</title></titleInfo><name type="personal"><namePart type="given">Hiroshi</namePart><namePart type="family">Nagayama</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><description>Correspondence: Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, 1‐1‐5 Sendagi Bunkyo‐ku, Tokyo 113‐8603, Japan</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masayuki</namePart><namePart type="family">Ueda</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mineo</namePart><namePart type="family">Yamazaki</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yasuhiro</namePart><namePart type="family">Nishiyama</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Makoto</namePart><namePart type="family">Hamamoto</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yasuo</namePart><namePart type="family">Katayama</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief communication" displayLabel="shortCommunication"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-08-15</dateIssued><dateCaptured encoding="w3cdtf">2009-11-22</dateCaptured><dateValid encoding="w3cdtf">2010-06-09</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="references">15</extent><extent unit="words">2338</extent></physicalDescription><abstract lang="en">[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: All authors have no financial disclosure or conflicts of interest related to this article.</note><subject lang="en"><genre>Keywords</genre><topic>MIBG</topic><topic>myocardial scintigraphy</topic><topic>multiple system atrophy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1744</start><end>1747</end><total>4</total></extent></part></relatedItem><identifier type="istex">0E7C00AA65D43F1FDA7276F00F617A72913D7337</identifier><identifier type="DOI">10.1002/mds.23338</identifier><identifier type="ArticleID">MDS23338</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001611 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001611 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337
|texte= Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |